Maze Therapeutics (MAZE) Revenue & Revenue Breakdown
Maze Therapeutics Revenue Highlights
00
Maze Therapeutics Revenue by Period
Maze Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | -100.00% |
| 2024-12-31 | $167.50M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | - |
Maze Therapeutics generated - in revenue during NA 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Maze Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | - | -100.00% |
| 2026-03-31 | $20.00M | 100.00% |
| 2025-12-31 | - | 100.00% |
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-12-31 | - | -100.00% |
| 2024-09-30 | $2.50M | -98.48% |
| 2024-06-30 | $165.00M | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | - |
Maze Therapeutics generated - in revenue during Q2 2026, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Maze Therapeutics Revenue Breakdown
Maze Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 26 |
|---|---|
| UNITED STATES | $20.00M |
Latest
Maze Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 26: UNITED STATES (100.00%).
Maze Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals | $874.84M | $218.25M |
| ARDX | Ardelyx | $407.32M | $120.88M |
| WVE | Wave Life Sciences | $42.73M | $2.27M |
| IMNM | Immunome | $6.94M | - |
| NTLA | Intellia Therapeutics | - | $7.66M |
| SION | Sionna Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| SYRE | Spyre Therapeutics | - | - |
| TRVI | Trevi Therapeutics | - | - |
| MAZE | Maze Therapeutics | - | - |
| ZYME | Zymeworks | $-27.11M | - |